Lecanemab: Looking Before We Leap.

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Lecanemab, an amyloid-sequestering agent, gained accelerated FDA approval for mild Alzheimer disease (AD) and mild cognitive impairment (MCI).
• Approval stemmed from the Clarity phase 3 trial, showing reduced amyloid plaques and cognitive decline.

Purpose of the Study:

• To critically evaluate the benefits, harms, and costs of lecanemab for AD and MCI treatment.
• To compare lecanemab's clinical significance against established benchmarks and existing therapies.

Main Methods:

• Analysis of data from the Clarity phase 3 trial for lecanemab.
• Comparison of lecanemab's effect size with minimally important clinical differences and cholinesterase inhibitors.
• Assessment of lecanemab's safety profile, including rates of brain edema and intracranial bleeding.
• Evaluation of lecanemab's projected costs and potential impact on healthcare expenditures.

Main Results:

• Lecanemab demonstrated statistically significant cognitive effects, but the effect size may not be clinically meaningful.
• Adverse events included symptomatic brain edema (11%) and intracranial bleeding (0.5%) in the trial.
• Projected annual healthcare costs for lecanemab could reach $120 billion if widely adopted.

Conclusions:

• Lecanemab's clinical benefits appear small relative to its significant harms and unprecedented costs.
• Real-world risks may exceed trial data due to medication interactions, older patient populations, and differing clinical settings.
• Further evidence is required to ascertain if lecanemab is superior to existing treatments like donepezil in terms of efficacy, safety, and cost-effectiveness.